PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.79%
Both yoy net incomes decline, with TRAW at -5.67%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-4.72%
Both reduce yoy D&A, with TRAW at -21.43%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-4.68%
Negative yoy SBC while TRAW is 6.44%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
284.52%
Well above TRAW's 109.62% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
299.08%
AP growth well above TRAW's 86.65%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-348.88%
Negative yoy usage while TRAW is 222.35%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
208.62%
Some yoy increase while TRAW is negative at -112.40%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
35.18%
Operating cash flow growth 1.25-1.5x TRAW's 24.39%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
82.00%
CapEx growth of 82.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.00%
We expand invests by 82.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.